Proteus Industries, Inc.

The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers. Biotechnology Innovation Organization Michelle McMurray Heath stepped down from her role as president and chief executive officer of BIO. She will now serve as an adviser to the executive committee, offering guidance on key BIO initiatives. During her short tenure as CEO, McMurry-Heath reorganized the leadership structure of the trade group to provide what was expected to be “long-term stability for the organization.” However, reports have suggested that stability has not been achieved. Rachel King, co-founder and former CEO of GlycoMimetics, Inc. has stepped in to serve as interim CEO. BIO will search for a full-time CEO. In addition to her role at GlycoMimetis, King served as a senior vice president at Novartis. Before that, she was CEO of Genetic Therapy, Inc. Passage Bio William Chou will assume the role of chief executive officer of Philadelphia-based Passage Bio. He replaces Edgar B. Cale, who has served as interim CEO. Cale will continue his role as general counsel and corporate secretary. Chou most recently served as CEO of Aruvant Sciences, a gene therapy company. Before Aruvant, he held multiple leadership roles at Novartis, including vice president, global disease lead for the company's Cell and Gene Therapy unit. Before Novartis, Chou worked at the Boston Consulting Group. Palisade Bio Thomas Hallam ceased his duties as CEO of Palisade on Oct. 10. JD Finley, the company’s current chief financial officer, has stepped in to serve as interim CEO. Prior to joining Palisade, Finley was president, CFO and CEO of PointAcross, Inc., a software company. Prior to that, he co-founded Proteus Capital Partners, Inc. New Chief Medical Officers Maze Therapeutics Harold Bernstein, M.D., Ph.D., has been appointed president, head of research and development and chief medical officer. Bernstein joins Maze from BioMarin, where he served as senior vice president, CMO and head of global clinical development. Prior to BioMarin, he was head of translational medicine and vice president of global medicines development and medical affairs at Vertex. Before that, he held roles at Merck, including head of early development for cardiometabolic diseases. Additionally, Eric Green, M.D., Ph.D., who has served as Maze’s senior vice president, research and translational sciences, has been promoted to chief scientific officer. Previously, Green was an entrepreneur-in-residence at Third Rock Ventures. Cerecin, Inc. Marc Cantillon, M.D. was named CMO of neurotherapeutics company Cerecin. Prior to Cerecin, Cantillon was CMO of Reviva Pharmaceuticals. Before that, he was CMO of Green Valley Pharmaceuticals. He has also held leadership roles at AstraZeneca, Impax Labs and Kyowa Kirin. Cantillon was also the founding executive medical director of the Coalition for Major Diseases at the Critical Path Institute, a public-private partnership. Walden Biosciences Peter Guest Linde, M.D. was named the first CMO of Walden Biosciences. Most recently, Linde was CMO of Morphic Therapeutic, Inc. Prior to that, he was vice president of medical research at Acceleron Pharma, Inc. Before that, Linde was project lead of clinical asset development at AbbVie. Before that, he was senior director of clinical development at FibroGen, Inc. In addition, Linde was founder, director and president of Triaxis Medical Devices, Inc. He started his corporate career at Johnson & Johnson, Inc., where he was the director of clinical research. Canary Medical Patrick Verta, M.D., was appointed CMO. He previously served as vice president of medical affairs, clinical science and biometrics at Edwards Lifesciences. Prior to his role at Edwards, Verta served as the company’s vice president of medical affairs and heart failure in the corporate development and strategy group. Previously, he served as CMO for start-up companies Sunshine Heart and Neomend. Before that, he served in various roles of increasing responsibility at Abbott Vascular and Guidant. Vor Bio Longtime industry executive Eyal C. Attar, M.D., was named CMO of Vor Bio. Attar most recently served as senior vice president and CMO for Aprea Therapeutics. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, including senior medical director and IDH hematology medical lead. Attar was previously an attending hematologist/oncologist at Massachusetts General Hospital. Maternova, Inc. Luna M. Mehrain, M.D., was tapped as CMO of Rhode Island-based Maternova. Mehrain previously held positions with Médecins Sans Frontières, Merlin, DAI, Population Services International and the International Planned Parenthood Federation.

Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Palisade Bio Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced an executive leadership transition. Effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as chief executive officer (CEO). The company’s board of directors has appointed JD Finley, current chief financial officer (CFO), as interim CEO, and Mr. Finley has assumed the duties of Dr. Hallam effective October 10, 2022. “On behalf of my fellow directors, I would like to thank Tom for his dedication to Palisade Bio over the last nine years,” said James R. Neal, chairman of the board of Palisade Bio. “Tom was instrumental in the development LB1148. We thank him for his contributions to the company and wish him the best in his future endeavors.” Mr. Neal continued, “During this time of transition, the board of directors believes that JD Finley is uniquely qualified to lead Palisade Bio and its continued advancement of LB1148. JD has served as Palisade’s CFO since 2017, during which time he led multiple financings and played a key role in the execution of the company’s 2021 merger with Seneca Biopharma, Inc., which resulted in Palisade Bio’s public listing on Nasdaq. We are pleased to name JD as interim CEO and we look forward to his continued contributions to the company.” “I have long been committed to the success of Palisade Bio and the clinical advancement of LB1148, and I am honored to assume this leadership role for the company,” said JD Finley, interim CEO of Palisade Bio. “I am a strong believer in the promise of LB1148 for the potential treatment of acute and chronic gastrointestinal complications, and I, along with our dedicated team, will continue the important work of advancing our programs for the benefit of our shareholders and patients worldwide.” Mr. Finley is an experienced financial executive, having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal CFO and an independent investment banker. Prior to joining Palisade Bio, Mr. Finley was the chief executive officer, president and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as executive vice president and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. In order to ensure a smooth and timely transition, the company will focus its near-term resources on the internal reorganization. Accordingly, the company will no longer be presenting at the American College of Surgeons (ACS) Clinical Congress 2022, being held October 16 – 20, 2022. About Palisade Bio Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. The company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a pivotal Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions. The company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to . Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company’s ability to achieve additional financing to fund clinical development and the company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com Source: Palisade Bio